Pharmacovigilance and Digital Transformation: Growing Role of Technology Digital Transformation and Industry 4.0 – these are the topics regularly featured in titles of Life Sciences events and publications recently. While we talk a lot about technologies that disrupt drug development, clinical trials, and pre-clinical stage processes, it is difficult to come across materials dedicated to…

Pharmacovigilance Europe Congress 22-23 May 2018 London, United Kingdom 4th Annual International Conference and Exhibition in Pharmacovigilance, Regulatory Affairs, Risk Management and Clinical Trials Official Event Website.

Pharmacovigilance is the process of detecting, tracking, analyzing, and preventing negative side effects of drugs. Pharmacovigilance allows manufacturers and regulators to continue studying drugs and their effects after the drugs are released. With the global pharmaceutical market worth over $1 trillion and growing at a projected cumulative annual growth rate (CAGR) of 6% from 2014 to 2020, added to the increasing…

Pharmacovigilance activities have long been fundamental to companies seeking market approval in both the drug and device development process. For this reason, many companies decide to outsource some of the their tasks in order to improve efficiency in managing their Pharmacovigilance Systems. However, once you know what functions and expertise you want to keep in-house…

The new Clinical Trials Regulation n° 536/2014 was adopted in 2014. Due to technical difficulties in the development of computer systems, the “go live” date of the Portal was postponed and the EMA Board of Directors will identify a new date once the provider confirms the resolution of the issues. Therefore, the EU Clinical Trials…

Pharmacovigilance Market size is expected to exceed USD 8 billion by 2024; according to a new research report by Global Market Insights, Inc. Growing number of adverse drug reactions (ADRs) coupled with increasing prevalence of chronic diseases will drive global pharmacovigilance market size. Below a snapshot from today to 2024: To download our infographic, click here. Continue…

Pharmacovigilance activities has long been fundamental to the pharmaceutical companies. As a result, demand for robust compliance systems and experienced talent have raised the cost of maintaining the infrastructure needed to support pharmacovigilance activities so, many companies decide to outsource some of their pharmacovigilance activities in order to improve effectiveness in managing their Pharmacovigilance Systems. For this…

Starting on the 22nd of November 2017, new improvements and changes will affect users of the EudraVigilance system, such as National Competent Authorities, Marketing Authorisation Holders and Sponsors of clinical trials. The European Medicines Agency (EMA) will launch a new and improved version of EudraVigilance with enhanced functionalities for reporting and analysing suspected adverse reactions….

seQure Life Sciences presents the current pharmacovigilance legislation in Europe:

DIA Europe 2018 17 – 19 April – Basel, Switzerland DIA Europe 2018 is more than just a traditional meeting. It’s a chance to learn, engage, and grow as a professional in health care. DIA Europe 2018 is unique in presenting the entire health care value chain ranging from policy and regulations to R&D, marketing and access….

©2017 - seQure - All Right Reserved - Privacy Policy - Cookie Policy